Meredith R. Metcalf, MD, discusses recent research evaluating management of clinical T1a RCC in men and women.
In this interview, Meredith R. Metcalf, MD, discusses a paper published in Urology titled "Gender Differences in the Clinical Management of Renal Cell Carcinoma," for which she served as a study author. Metcalf is instructor of urology at Johns Hopkins University, Baltimore.
More videos:
Prolapse surgery outcomes compared in nursing home residents, community-dwelling adults
Effect of an online opioid training course on prescription patterns for urologic surgeries
Sperm parameters maintained in most men taking nasal testosterone gel
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.